This is a newsletter from NextBioForm, a center coordinated by RISE with the goal to deliver better formulations for biopharmaceuticals. From the long-term perspective, our goal is to create stable biopharmaceuticals that will improve the quality of life for patients.
Read past NextBioForm newsletters and subscribe here |
|
| Summer is getting close, and we are all looking forward to a well-deserved holiday period after an intense spring term. The partners in NextBioForm met in Lund in the beginning of May to discuss the future of formulation and drug delivery for biologics. Read more about this exciting meeting below. |
| Read more |
|
|
With the arrival of spring, we all meet in Lund for the spring centre meeting. The theme for the meetings was The future of biologics. The meeting was split over two days, where the first day focused on inspirational presentations from participants of NextBioForm and external speakers on the topic of the future of biologics.
Read more |
|
|
|
We interviewed Dr Ann Terry, Group manager for Diffraction and Scattering at MAX IV and Beam line manager for CoSAXS, about the connection between MAX IV and NextBioForm.
MAX IV Laboratory is a Swedish national synchrotron laboratory that has operated as a user facility since 2016. MAX IV offers access to 16 beamlines that provide modern X-ray spectroscopy, scattering/diffraction, and imaging techniques to contribute to solving scientific questions in a wide range of areas.
Read more |
|
|
|
NextBioForm, together with SweDeliver, organizes the conference "New Horizon on drug delivery and formulation" on November 27-29 2023 at Uppsala Konsert & Kongress in Uppsala.
Read more |
|
|
|
Authors: Amanda Västberg, Hans Bolinsson, Mats Leeman, Lars Nilsson, Tommy Nylander, Kushal Sejwal, Ida-Maria Sintorn, Kristina Lidayová, Helen Sjögren, Marie Wahlgren and Ulla Elofsson. |
Therapeutic proteins are a growing segment in the pharmaceutical industry. However, one challenge is the formation of protein aggregates. Due to the broad range in size, concentration, and shape, it is necessary to use a combination of techniques for the characterization.
By combining scattering (DLS), fractionation (AF4), and imaging (MiniTEM™) it was possible to show that Somatropin followed a two-step aggregation pathway at pH 7 during heating. First, small, elongated aggregates were formed that, in the second step, clustered together to form larger, more complex aggregates.
The addition of an imaging technique to illustrate the aggregates was shown to be powerful in combination with DLS and AF4 to describe the aggregation pathway for aggregates <100 nm.
Link to the publication, published in International Journal of Pharmaceutics
|
|
|
